KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Operating Leases (2019 - 2021)

Abbott Laboratories (ABT) has disclosed Operating Leases for 3 consecutive years, with $956.0 million as the latest value for Q4 2021.

  • Quarterly Operating Leases rose 5.99% to $956.0 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $956.0 million through Dec 2021, up 5.99% year-over-year, with the annual reading at $956.0 million for FY2021, 5.99% up from the prior year.
  • Operating Leases hit $956.0 million in Q4 2021 for Abbott Laboratories, up from $902.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $956.0 million in Q4 2021 to a low of $755.0 million in Q4 2019.
  • Historically, Operating Leases has averaged $871.0 million across 3 years, with a median of $902.0 million in 2020.
  • Biggest five-year swings in Operating Leases: rose 19.47% in 2020 and later increased 5.99% in 2021.
  • Year by year, Operating Leases stood at $755.0 million in 2019, then increased by 19.47% to $902.0 million in 2020, then rose by 5.99% to $956.0 million in 2021.
  • Business Quant data shows Operating Leases for ABT at $956.0 million in Q4 2021, $902.0 million in Q4 2020, and $755.0 million in Q4 2019.